|
RESEARCH
|
Fuyu Tamanoi, Ph.D.
Contact Information:
Fax Number:
310-206-5231
Work Phone Number:
310-206-7318
310-825-7450
310-825-7754
Laboratory Address:
Tamanoi Laboratory Molecular Science Building 2711, 2715 Los Angeles, CA 90095 UNITED STATES
Office Address:
405 Hilgard Avenue Los Angeles, CA 90095 UNITED STATES
Work Address:
UCLA MIMG Molecular Science Building 2610A BOX 951489 Los Angeles, CA 90095 UNITED STATES
Director,
JCCC Signal Transduction and Therapeutics Program Area |
Co-Group Leader,
NanoBiotechnology and Biomaterials
|
Professor and Vice Chair,
Microbiology, Immunology & Molecular Genetics
|
Member,
ACCESS Program: Dept. of Microbiology, Immunology, & Molecular Genetics
CTSI
California NanoSystems Institute
|
Faculty,
Molecular Biology IDP
|
|
A Short Biography:
Fuyu Tamanoi is a biochemist who has served on the UCLA School of Medicine and UCLA College faculty since he joined the Department of Microbiology, Immunology & Molecular Genetics in 1993. He became a full professor in 1997. Since 1996, he has been a Director of Signal Transduction Program Area at Jonsson Comprehensive Cancer Center. Dr. Tamanoi earned his B.S. and M.S. in Biochemistry at the University of Tokyo. He received PhD in Molecular Biology at Nagoya University in 1977. He was a postdoctoral fellow at Harvard Medical School, where he worked on bacteriophage DNA replication. From 1980 to 1985, he was a senior staff investigator at Cold Spring Harbor Laboratory, where he worked on adenovirus DNA replication. From 1985 to 1993, he was an Assistant Professor and then Associate Professor at the University of Chicago, where he initiated studies on lipid modification of the Ras family proteins. His laboratory research centers on signal transduction and signal transduction inhibitors. He is currently exploring ways to deliver signal transduction inhibitors using nanoparticles.
Awards and Honors:
American Society for Biochemistry & Molecular Biology
American Association for Cancer Research
Hardt M, Chantaravisoot N, Tamanoi F Activating mutations of TOR (target of rapamycin).
Genes Cells.
2011;
16(2):
141-51.
Huan Meng, Min Xue, Tian Xia, Yan-Li Zhao, Fuyuhiko Tamanoi, J. Fraser Stoddart, Jeffrey I. Zink and Andre E. Nel Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive Nanovalves.
J. Am. Chem. Soc..
2010;
132(36):
12690-7.
Jie Lu, Monty Liong, Zongxi Li, Jeffrey I. Zink, Fuyuhiko Tamanoi Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals.
Small.
2010;
6(16):
1794-1805.
A B Hanker, N Mitin, R S Wilder, E P Henske, F Tamanoi, A D Cox and C J Der Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling.
Oncogene.
2010;
29:
380?391.
Nakashima A, Sato T, Tamanoi F Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin.
J Cell Sci.
2010;
123(Pt 5):
777-85.
Jiang H, Song C, Chen CC, Xu R, Raines KS, Fahimian BP, Lu CH, Lee TK, Nakashima A, Urano J, Ishikawa T, Tamanoi F, Miao J Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy.
Proc Natl Acad Sci U S A.
2010;
107(25):
11234-9.
Chan LN, Hart C, Guo L, Nyberg T, Davies BS, Fong LG, Young SG, Agnew BJ, Tamanoi F A novel approach to tag and identify geranylgeranylated proteins.
Electrophoresis.
2009;
30(20):
3598-606.
Kugawa, F. Suzuki, T. Miyata, M. Tomono, K. Tamanoi, F. Construction of a model cell line for the assay of MDR1 (Multi Drug Resistance gene-1) substrates/inhibitors using HeLa cells.
Pharmazie.
2009;
64(5):
296-300.
Lu, J. Chan, L. Fiji, H. D. G. Dahl, R. Kwon, O. Tamanoi, F. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I.
Molecular Cancer Therapeutics.
2009;
8(5):
1218-1226.
Klichko, Y. Liong, M. Choi, E. Angelos, S. Nel, A. E. Stoddart, J. F. Tamanoi, F. Zink, J. I. Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery.
Journal of the American Ceramic Society.
2009;
92(1):
S2-S10.
Sato, T. Umetsu, A. Tamanoi, F. Characterization of the Rheb-mTOR signaling pathway in mammalian cells: Constitutive active mutants of Rheb and mTOR.
Small Gtpases in Disease, Part A.
2008;
438:
307-320.
Jie Lu, Eunshil Choi, Fuyuhiko Tamanoi, Jeffrey I. Zink Light-Activated Nanoimpeller-Controlled Drug Release in Cancer Cells.
Small .
2008;
4(4):
421-426.
Liong, M. Lu, J. Kovochich, M. Xia, T. Ruehm, S. G. Nel, A. E. Tamanoi, F. Zink, J. I. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery.
Acs Nano.
2008;
2(5):
889-896.
Aspuria, P. J. Tamanoi, F. The Tsc/Rheb signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast.
Molecular Genetics and Genomics.
2008;
279(5):
441-450.
Matsuo, T. Otsubo, Y. Urano, J. Tamanoi, F. Yamamoto, M. Loss of the TOR kinase Tor2 mimics nitrogen starvation and activates the sexual development pathway in fission yeast.
Molecular and Cellular Biology.
2007;
27(8):
3154-3164.
Lu, J. Liong, M. Zink, J. I. Tamanoi, F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs.
Small.
2007;
3(8):
1341-1346.
Yu, F. Q. Harada, J. N. Brown, H. J. Deng, H. Y. Song, M. J. Wu, T. T. Kato-Stankiewicz, J. Nelson, C. G. Vieira, J. Tamanoi, F. Chanda, S. K. Sun, R. Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus.
Plos Pathogens.
2007;
3(3):
e44.
P.H. Patel and F. Tamanoi Increased Rheb/TOR signaling enhances sensitivity of the whole organism to oxidative stress.
J. Cell. Sci. .
2006;
119(20):
4285-4292.
Ikeda, A. Shankar, D. B. Watanabe, M. Tamanoi, F. Moore, T. B. Sakamoto, K. M. Molecular targets and the treatment of myeloid leukemia.
Molecular Genetics and Metabolism.
2006;
88(3):
216-224.
A.P. Tabancay Jr., M.J. Comiso and F. Tamanoi RAS family G-proteins in Saccharomyces cerevisiae and Schizosaccharomyces pombe.
RAS family GTPases.
2006;
4:
277-256.
Gelb, M. H. Brunsveld, L. Hrycyna, C. A. Michaelis, S. Tamanoi, F. Van Voorhis, W. C. Waldmann, H. Therapeutic intervention based on protein prenylation and associated modifications.
Nature Chemical Biology.
2006;
2(10):
518-528.
P.H. Patel, and F. Tamanoi Using Drosophila and yeast genetics to investigate a role for the Rheb GTPase in cell growth.
Methods in Enzymol..
2006;
407:
443-454.
Khazak, V. Kato-Stankiewicz, J., Tamanoi, F, and Golemis, E.A. Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction.
Methods in Enzymol..
2006;
407:
612-629.
Gau CL, Kato-Stankiewicz J, Jiang C, Miyamoto S, Guo L and Tamanoi F Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and insensitive pathways.
Molecular Cancer Therapeutics.
2005;
4(6):
918-926.
Urano, J. Comiso, M. J. Guo, L. Aspuria, P. J. Deniskin, R. Tabancay, A. P. Kato-Stankiewicz, J. Tamanoi, F. Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast.
Molecular Microbiology.
2005;
58(4):
1074-1086.
Patel, P.H., Thapar, N., Guo, L., Martinez, M., Maris, J., Gau, C-L., Lengyel, J.A. and Tamanoi, F. Drosophila RHEB GTPase is required for cell cycle progression and cell growth.
Journal of Cell Science.
2003;
116:
3601-3610.
Yang, W. L. Tabancay, A. P. Urano, J. Tamanoi, F. Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant.
Molecular Microbiology.
2001;
41(6):
1339-1347.
Tamanoi, F. Gau, C. L. Jiang, C. Edamatsu, H. Kato-Stankiewicz, J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Cellular and Molecular Life Sciences.
2001;
58(11):
1636-1649.
Guo, W. Tamanoi, F. Novick, P. Spatial regulation of the exocyst complex by Rho1 GTPase.
Nature Cell Biology.
2001;
3(4):
353-360.
Ferris Daniel P, Lu Jie, Gothard Chris, Yanes Rolando, Thomas Courtney R, Olsen John-Carl, Stoddart J Fraser, Tamanoi Fuyuhiko, Zink Jeffrey I Synthesis of biomolecule-modified mesoporous silica nanoparticles for
targeted hydrophobic drug delivery to cancer cells..
Small (Weinheim an der Bergstrasse, Germany).
2011;
7(13):
1816-26.
Lu Jie, Li Zongxi, Zink Jeffrey I, Tamanoi Fuyuhiko In vivo tumor suppression efficacy of mesoporous silica
nanoparticles-based drug-delivery system: enhanced efficacy by folate
modification..
Nanomedicine : nanotechnology, biology, and medicine.
2011;
133(23):
.
Xue Min, Zhong Xing, Shaposhnik Zory, Qu Yongquan, Tamanoi Fuyuhiko, Duan Xiangfeng, Zink Jeffrey I pH-Operated mechanized porous silicon nanoparticles..
Journal of the American Chemical Society.
2011;
133(23):
8798-801.
Tamanoi Fuyuhiko Ras signaling in yeast..
Genes & cancer.
2011;
2(3):
210-5.
Meng Huan, Xue Min, Xia Tian, Zhao Yan-Li, Tamanoi Fuyuhiko, Stoddart J Fraser, Zink Jeffrey I, Nel Andre E Autonomous in vitro anticancer drug release from mesoporous silica
nanoparticles by pH-sensitive nanovalves..
Journal of the American Chemical Society.
2010;
132(36):
12690-7.
Lu Jie, Liong Monty, Li Zongxi, Zink Jeffrey I, Tamanoi Fuyuhiko Biocompatibility, biodistribution, and drug-delivery efficiency of
mesoporous silica nanoparticles for cancer therapy in animals..
Small (Weinheim an der Bergstrasse, Germany).
2010;
6(16):
1794-805.
Hom Christopher, Lu Jie, Liong Monty, Luo Hanzhi, Li Zongxi, Zink Jeffrey I, Tamanoi Fuyuhiko Mesoporous silica nanoparticles facilitate delivery of siRNA to
shutdown signaling pathways in mammalian cells..
Small (Weinheim an der Bergstrasse, Germany).
2010;
6(11):
1185-90.
Jiang Huaidong, Song Changyong, Chen Chien-Chun, Xu Rui, Raines Kevin S, Fahimian Benjamin P, Lu Chien-Hung, Lee Ting-Kuo, Nakashima Akio, Urano Jun, Ishikawa Tetsuya, Tamanoi Fuyuhiko, Miao Jianwei Quantitative 3D imaging of whole, unstained cells by using X-ray
diffraction microscopy..
Proceedings of the National Academy of Sciences of the United States of America.
2010;
107(25):
11234-9.
Hom, C., Lu, J., Liong, M., Luo, H., Li, Z., Zink, J.I., Tamanoi, F. Mesoporous Silica Nanoparticles Facilitate Delivery of siRNA to Shutdown Signaling Pathways in Mammalian Cells.
Small.
2010;
6(11):
1185-90.
Nakashima Akio, Sato Tatsuhiro, Tamanoi Fuyuhiko Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins
in response to nutrients and its activity is inhibited by rapamycin..
Journal of cell science.
2010;
123(Pt 5):
777-86.
Chan Lai N, Hart Courtenay, Guo Lea, Nyberg Tamara, Davies Brandon S J, Fong Loren G, Young Stephen G, Agnew Brian J, Tamanoi Fuyuhiko A novel approach to tag and identify geranylgeranylated proteins..
Electrophoresis.
2009;
30(20):
3598-606.
Sato, T. Nakashima, A. Guo, L. Tamanoi, F. Specific Activation of mTORC1 by Rheb G-protein in Vitro Involves Enhanced Recruitment of Its Substrate Protein.
Journal of Biological Chemistry.
2009;
284(19):
12783-12791.
Lu Jie, Chan Lai, Fiji Hannah D G, Dahl Russell, Kwon Ohyun, Tamanoi Fuyuhiko In vivo antitumor effect of a novel inhibitor of protein
geranylgeranyltransferase-I..
Molecular cancer therapeutics.
2009;
8(5):
1218-26.
Sato Tatsuhiro, Nakashima Akio, Guo Lea, Tamanoi Fuyuhiko Specific activation of mTORC1 by Rheb G-protein in vitro involves
enhanced recruitment of its substrate protein..
The Journal of biological chemistry.
2009;
284(19):
12783-91.
Zhou, J. Vos, C. C. Gjyrezi, A. Yoshida, M. Khuri, F. R. Tamanoi, F. Giannakakou, P. The Protein Farnesyltransferase Regulates HDAC6 Activity in a Microtubule-dependent Manner.
Journal of Biological Chemistry.
2009;
284(15):
9648-9655.
Davies Brandon S J, Yang Shao H, Farber Emily, Lee Roger, Buck Suzanne B, Andres Douglas A, Spielmann H Peter, Agnew Brian J, Tamanoi Fuyuhiko, Fong Loren G, Young Stephen G Increasing the length of progerin's isoprenyl anchor does not worsen
bone disease or survival in mice with Hutchinson-Gilford progeria
syndrome..
Journal of lipid research.
2009;
50(1):
126-34.
Hom Christopher, Lu Jie, Tamanoi Fuyuhiko Silica nanoparticles as a delivery system for nucleic acid-based
reagents..
Journal of materials chemistry.
2009;
19(35):
6308-6316.
Short, J. D. Houston, K. D. Dere, R. Cai, S. L. Kim, J. Johnson, C. L. Broaddus, R. R. Shen, J. J. Miyamoto, S. Tamanoi, F. Kwiatkowski, D. Mills, G. B. Walker, C. L. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27.
Cancer Research.
2008;
68(16):
6496-6506.
Liong Monty, Lu Jie, Kovochich Michael, Xia Tian, Ruehm Stefan G, Nel Andre E, Tamanoi Fuyuhiko, Zink Jeffrey I Multifunctional inorganic nanoparticles for imaging, targeting, and
drug delivery..
ACS nano.
2008;
2(5):
889-96.
Aspuria Paul-Joseph, Tamanoi Fuyuhiko The Tsc/Rheb signaling pathway controls basic amino acid uptake via
the Cat1 permease in fission yeast..
Molecular genetics and genomics : MGG.
2008;
279(5):
441-50.
Watanabe, M. Fiji, H. D. G. Guo, L. Chan, L. Kinderman, S. S. Slamon, D. J. Kwon, O. Tamanoi, F. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds.
Journal of Biological Chemistry.
2008;
283(15):
9571-9579.
Watanabe Masaru, Fiji Hannah D G, Guo Lea, Chan Lai, Kinderman Sape S, Slamon Dennis J, Kwon Ohyun, Tamanoi Fuyuhiko Inhibitors of protein geranylgeranyltransferase I and Rab
geranylgeranyltransferase identified from a library of
allenoate-derived compounds..
The Journal of biological chemistry.
2008;
283(15):
9571-9.
Sato Tatsuhiro, Umetsu Akiko, Tamanoi Fuyuhiko Characterization of the Rheb-mTOR signaling pathway in mammalian
cells: constitutive active mutants of Rheb and mTOR..
Methods in enzymology.
2008;
438(3):
307-20.
Ikeda, K. Morigasaki, S. Tatebe, H. Tamanoi, F. Shiozaki, K. Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control.
Cell Cycle.
2008;
7(3):
358-364.
Aspuria, P. J. Sato, T. Tamanoi, F. The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells.
Cell Cycle.
2007;
6(14):
1692-1695.
Aspuria Paul-Joseph, Sato Tatsuhiro, Tamanoi Fuyuhiko The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian
cells: temperature sensitive and constitutive active mutants of TOR..
Cell cycle (Georgetown, Tex.).
2007;
6(14):
1692-5.
Castellano, S. Fiji, H. D. G. Kinderman, S. S. Watanabe, M. de Leon, P. Tamanoi, F. Kwon, O. Small-molecule inhibitors of protein geranylgeranyltransferase type I.
Journal of the American Chemical Society.
2007;
129(18):
5843-+.
Castellano Sabrina, Fiji Hannah D G, Kinderman Sape S, Watanabe Masaru, Leon Pablo de, Tamanoi Fuyuhiko, Kwon Ohyun Small-molecule inhibitors of protein geranylgeranyltransferase type I..
Journal of the American Chemical Society.
2007;
129(18):
5843-5.
Yu Fuqu, Harada Josephine N, Brown Helen J, Deng Hongyu, Song Moon Jung, Wu Ting-Ting, Kato-Stankiewicz Juran, Nelson Christian G, Vieira Jeffrey, Tamanoi Fuyuhiko, Chanda Sumit K, Sun Ren Systematic identification of cellular signals reactivating Kaposi
sarcoma-associated herpesvirus..
PLoS pathogens.
2007;
3(3):
e44.
Patel Parthive H, Tamanoi Fuyuhiko Increased Rheb-TOR signaling enhances sensitivity of the whole
organism to oxidative stress..
Journal of cell science.
2006;
119(Pt 20):
4285-92.
Patel Parthive H, Tamanoi Fuyuhiko Using Drosophila and yeast genetics to investigate a role for the Rheb
GTPase in cell growth..
Methods in enzymology.
2006;
407(10):
443-54.
Urano Jun, Comiso Melissa J, Guo Lea, Aspuria Paul-Joseph, Deniskin Roman, Tabancay Angel P, Kato-Stankiewicz Juran, Tamanoi Fuyuhiko Identification of novel single amino acid changes that result in
hyperactivation of the unique GTPase, Rheb, in fission yeast..
Molecular microbiology.
2005;
58(4):
1074-86.
Gau Chia-Ling, Kato-Stankiewicz Juran, Jiang Chen, Miyamoto Susie, Guo Lea, Tamanoi Fuyuhiko Farnesyltransferase inhibitors reverse altered growth and distribution
of actin filaments in Tsc-deficient cells via inhibition of both
rapamycin-sensitive and -insensitive pathways..
Molecular cancer therapeutics.
2005;
4(6):
918-26.
Aspuria PJ, Tamanoi F The Rheb family of GTP-binding proteins.
Cellular signalling.
2004;
16(10):
1105-12.
Aspuria Paul-Joseph, Tamanoi Fuyuhiko The Rheb family of GTP-binding proteins..
Cellular signalling.
2004;
16(10):
1105-12.
Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao Y A tagging-via-substrate technology for detection and proteomics of farnesylated proteins..
Proceedings of the National Academy of Sciences of the United States of America. .
2004;
101(34):
12479-84.
Uhlmann, E. J. Li, W. Scheidenhelm, D. K. Gau, C. L. Tamanoi, F. Gutmann, D. H. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation.
Glia.
2004;
47(2):
180-188.
Tabancay, A. P. Gau, C. L. Machado, I. M. P. Uhlmann, E. J. Gutmann, D. H. Guo, L. Tamanoi, F. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K.
Journal of Biological Chemistry.
2003;
278(41):
39921-39930.
Tabancay Angel P, Gau Chia-Ling, Machado Iara M P, Uhlmann Erik J, Gutmann David H, Guo Lea, Tamanoi Fuyuhiko Identification of dominant negative mutants of Rheb GTPase and their
use to implicate the involvement of human Rheb in the activation of
p70S6K..
The Journal of biological chemistry.
2003;
278(41):
39921-30.
Patel Parthive H, Thapar Nitika, Guo Lea, Martinez Monica, Maris John, Gau Chia-Ling, Lengyel Judith A, Tamanoi Fuyuhiko Drosophila Rheb GTPase is required for cell cycle progression and cell
growth..
Journal of cell science.
2003;
116(Pt 17):
3601-10.
Kato-Stankiewicz, J. Hakimi, I. Zhi, G. Zhang, J. Serebriiskii, I. Guo, L. Edamatsu, H. Koide, H. Menon, S. Eckl, R. Sakamuri, S. Lu, Y. C. Chen, Q. Z. Agarwal, S. Baumbach, W. R. Golemis, E. A. Tamanoi, F. Khazak, V. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.
Proceedings of the National Academy of Sciences of the United States of America.
2002;
99(22):
14398-14403.
Kato-Stankiewicz Juran, Hakimi Irina, Zhi Gang, Zhang Jie, Serebriiskii Ilya, Guo Lea, Edamatsu Hironori, Koide Hiroshi, Menon Sanjay, Eckl Robert, Sakamuri Sukumar, Lu Yingchun, Chen Quin-Zene, Agarwal Seema, Baumbach William R, Golemis Erica A, Tamanoi Fuyuhiko, Khazak Vladimir Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening
revert Ras-dependent transformation phenotypes in human cancer cells..
Proceedings of the National Academy of Sciences of the United States of America.
2002;
99(22):
14398-403.
Finlin, B. S. Gau, C. L. Murphy, G. A. Shao, H. P. Kimel, T. Seitz, R. S. Chiu, Y. F. Botstein, D. Brown, P. O. Tamanoi, F. Andres, D. A. Perou, C. M. RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer.
Journal of Biological Chemistry.
2001;
276(45):
42259-42267.
Pervin, S. Singh, R. Gau, C. L. Edamatsu, H. Tamanoi, F. Chaudhuri, G. Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: Implications in breast cancer.
Cancer Research.
2001;
61(12):
4701-4706.
Edamatsu, H. Gau, C. L. Nemoto, T. Guo, L. Tamanoi, F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Oncogene.
2000;
19(27):
3059-3068.
Urano, J. Tabancay, A. P. Yang, W. L. Tamanoi, F. The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake.
Journal of Biological Chemistry.
2000;
275(15):
11198-11206.
Yang, W. L. Urano, J. Tamanoi, F. Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in Schizosaccharomyces pombe.
Journal of Biological Chemistry.
2000;
275(1):
429-438.
|
